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Objectives: Hesitance and resistance to COVID-19 vaccination poses a serious challenge to achieving
adequate vaccine uptake in the general population. Cross-sectional data from the early months of the
pandemic indicates that approximately one-third of adults in multiple nations are hesitant or resistant to
a vaccine for COVID-19. Using longitudinal data, we tracked changes in attitudes to COVID-19 vaccination
during the pandemic.
Study design: This is a quantitative, longitudinal design.
Method: Nationally representative samples of the adult general population of the Republic of Ireland
(N ¼ 1041) and the United Kingdom (N ¼ 2025) were assessed for their attitudes towards COVID-19
vaccination at three points from March to August 2020.
Results: Statistically significant increases in resistance to COVID-19 vaccination were observed in Irish
(from 9.5% to 18.1%) and British (from 6.2% to 10%) adults.
Conclusion: Resistance to vaccination has significantly increased in two European nations as the
pandemic has progressed. Growing resistance to COVID-19 vaccination will pose a challenge to public
health officials responsible for ensuring sufficient vaccine coverage.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).With an excess of 65 million confirmed cases across 190 coun-
tries globally and more than 1.5 million deaths, COVID-19 remains
one of the most important global health challenges of our lifetime.1
Recent announcements about the development of multiple, safe
and effective vaccines for COVID-19 offer a promising solution to
this public health crisis. However, in addition to production and
distribution challenges, a key challenge remains convincing a crit-
ical mass of the population to accept a COVID-19 vaccine.
In June 2020, 72% of people from 19 countries indicated that
they would accept a COVID-19 vaccine, with rates as high as 89% in
China and as low as 55% in Russia.2 An ongoing Gallup Poll of the
United States general population found that acceptance of a COVID-y, Maynooth University, Kil-
r Ltd on behalf of The Royal Society19 vaccine fell from 66% in July to 50% in September before
increasing to 58% by the end of October.3 Although more longitu-
dinal research is clearly required, early evidence suggests that
people's attitudes towards a COVID-19 vaccine are fluctuating over
time.
In March 2020, our research group initiated a longitudinal
project that tracked nationally representative samples of adults
from the Republic of Ireland and the United Kingdom (UK). Asked if
they would accept a hypothetical vaccine for COVID-19, approxi-
mately two-thirds of Irish (65%) and British (69%) adults responded
‘yes’, about one-quarter responded ‘maybe’ (26% in Ireland and 25%
in the UK) and the remainder responded ‘no’ (9% in Ireland and 6%
in the UK).4 Here, we report changes in COVID-19 vaccine accep-
tance (‘yes’), hesitance (‘maybe’) and resistance (‘no’) in these
samples during the first four months of the pandemic.
Identical sampling methods were used to collect data in Ireland
and the UK. Participants were recruited from existing survey panelsfor Public Health. This is an open access article under the CC BY license (http://crea
Table 1
Proportion of Irish (n ¼ 1030) and UK (n ¼ 2020) samples accepting, hesitant to and resistant to a COVID-19 vaccine.
Country Wave 1 Wave 2 Wave 3 Pairwise comparisons (Wald chi-squared)
% (95% CI) % (95% CI) % (95% CI) Wave 1 vs wave 2 Wave 1 vs wave 3 Wave 2 vs wave 3
Ireland
Acceptance 64.9 (61.9, 67.8) 64.3 (60.5, 68.1) 55.4 (51.6, 59.3) Chi-squared ¼ 0.09 Chi-squared ¼ 24.67*** Chi-squared ¼ 22.05***
Hesitance 25.6 (22.9, 28.3) 23.0 (19.5, 26.4) 26.6 (23.0, 30.2) Chi-squared ¼ 2.02 Chi-squared ¼ 0.23 Chi-squared ¼ 3.08
Resistance 9.5 (7.7, 11.3) 12.9 (10.1, 15.6) 18.1 (15.0, 21.2) Chi-squared ¼ 6.27* Chi-squared ¼ 30.24*** Chi-squared ¼ 11.03***
UK
Acceptance 68.8 (66.8, 70.9) 66.6 (64.3, 69.0) 71.8 (69.4, 74.3) Chi-squared ¼ 3.12 Chi-squared ¼ 5.53* Chi-squared ¼ 18.97***
Hesitance 24.9 (23.1, 26.8) 23.8 (21.7, 26.0) 18.1 (16.0, 20.2) Chi-squared ¼ 0.88 Chi-squared ¼ 30.29*** Chi-squared ¼ 23.54***
Resistance 6.2 (5.2, 7.3) 9.4 (7.9, 10.9) 10.0 (8.4, 11.7) Chi-squared ¼ 17.68*** Chi-squared ¼ 20.57*** Chi-squared ¼ 0.51
95% CI ¼ 95% confidence interval; UK, United Kingdom.
All degrees of freedom ¼ 1
* P < .05.
** P < .01.
*** P < .001.
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representative of their populations by sex, age, regional and income
distributions.4,5 In Ireland, wave 1 (N ¼ 1041) longitudinal data
were collected fromMarch 30 to April 5, wave 2 (n¼ 506, recontact
rate¼ 49%) datawere collected from April 30 to May 19 and wave 3
(n ¼ 534, recontact rate ¼ 51%) data were collected from July 16 to
August 8. In the UK, wave 1 (N ¼ 2025) longitudinal data were
collected from March 23 to 28, wave 2 (n ¼ 1,406, recontact
rate ¼ 69%) data were collected from April 22 to May 1 and wave 3
(n ¼ 1,166, recontact rate ¼ 58%) data were collected from July 9 to
August 9.
At each assessment, participants were asked ‘If a new vaccine
were to be developed that could prevent COVID-19, would you
accept it for yourself?’ Response options were ‘yes’, ‘maybe’ and
‘no’. Changes in COVID-19 vaccine acceptance (‘yes’), hesitance
(‘maybe) and resistance (‘no’) were assessed using a structural
equation modelling framework modelling, and missing data were
handled using robust maximum likelihood estimation.6,7 A ‘null’
model was initially specified wherein the proportions (e.g., in
vaccine resistance) were constrained to be equal over time. Next,
an ‘alternative’ model was specified wherein the proportions
were freely estimated over time. These models differ by one
degree of freedom, so improvement in model fit can be tested
using a log-likelihood ratio test that is distributed as a chi-
squared distribution. Finally, pairwise comparisons were tested
using a Wald chi-squared test. All analyses were performed in
Mplus, version 8.2.8
There were statistically significant changes over time in atti-
tudes towards COVID-19 vaccination in the Irish (chi-squared (2,
1030) ¼ 33.37, P < .001) and British (chi-squared (2, 2020) ¼ 19.22,
P < .001) samples. Table 1 reports all figures including the pairwise
comparisons. In Ireland, between March and August 2020, there
was a significant decrease in vaccine acceptance (from 64.9% to
55.4%), no change in vaccine hesitance (25.6e26.6%) and a signifi-
cant increase in vaccine resistance (9.5e18.1%). During the same
period in the UK, there was a significant increase in vaccine
acceptance (68.8e71.8%), a significant decrease in vaccine hesi-
tance (24.9e18.1%) and a significant increase in vaccine resistance
(6.2e10.0%).
Substantial changes in attitudes towards a vaccine for COVID-19
were evident in Irish and British adults during the first four months
of the pandemic. Resistance to COVID-19 vaccination rose in Ireland
by 91% and in the UK by 61%. It was notable that the changes in
attitudes towards COVID-19 vaccination changed in distinct ways in
the two countries. The rise in vaccine resistance in Ireland was55associated with a concomitant fall in vaccine acceptance, whereas
in the UK, the rise in vaccine acceptance and resistance was asso-
ciated with a parallel fall in vaccine hesitance.
The levels of vaccine acceptance identified in Ireland and the UK
during the earliest phase of the pandemic were similar to the
average level of vaccine acceptance across 19 nations reported by
Lazarus et al.2 in June 2020. However, the increased rate of vaccine
resistance observed in both countries by August 2020 mirrors
similar trends observed in the United States at a similar period of
time.3 It appears that the rise in vaccine resistance coincided with
the loosening of public health restrictions in these countries during
the summermonths as the spread of the virus began to come under
control and normal daily functioning formany people resumed. The
emergence of the ‘second wave’ of COVID-19 appears to have led to
an increase in vaccine acceptance in the United States,3 and it will
be important to understand if similar trends are observed in other
nations.
Moreover, the emergence and public distribution of actual
vaccines for COVID-19 may shift public attitudes further, which
presents an opportunity to assess how COVID-19 vaccine accep-
tance, hesitance and resistance change in the context of an
available vaccine; what predicts change in attitudes towards
vaccination and how well attitudes towards a hypothetical vac-
cine predict actual vaccine uptake. Timely, evidence-based an-
swers to these questions will provide valuable public health
information to health officials and policymakers to better inform
social behaviour and communications strategies to increase the
uptake of a COVID-19 vaccine.
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